A. Introduction
- Caused by bacteria of genus Brucella
- Pleiomorphic gram negative coccobacilli
- B. abortus - cattle borne (most common in USA), buffalo, camals, yaks
- B. melitensis - borne by sheep, goats, camels
- Very uncommon: B. suis (swine borne) and B. canis (canine borne)
- Very uncommon: B. ovis (sheep borne) and B. neotomae (rodent borne)
- Belongs to alpha2 subdivision of Proteobacteria including rikettsia
- Risks for Brucella Infection
- Humans develop disease by contact, ingestion, or inhalation
- Mainly associated with interactions with farm animals
- B. canis associated with some dog bites particularly beagles [4]
- Increased risk of contracting with travel to Middle East [6]
- Handling raw meat and eating unpasteurized cheese increase risk
- Cases By Country (Table 1, Ref [1])
- <150 cases / year in USA
- Syria, Iran, Turkey have >14,000 cases per year
- Mexico and Algeria have ~3000 cases per year
- No documented person to person transmission
- Facultative macrophage intracellular parasites
- Previously called undulant fever
B. Symptoms and Signs [2]
- Often asymptomatic
- Fever, anemia, nonspecific constitutional symptoms - large differential [3]
- Types of Disease
- Acute
- Localized
- Chronic / Progressive
- Usually homes to organs high in macrophages
- Includes spleen, liver, lungs, central nervous system, bone marrow
- Acute Disease
- Low grade fever without localization
- Systemic Symptoms: malaise, weakness, fatigue, sweats, weight loss
- Myalgia and backache may occur (± frank spondylitis)
- Hepatomegaly ~35%
- Splenomegaly and/or lymphadenopathy ~20% of patients
- Localized Disease
- Any location, especially osteomyelitis, splenic abscess, UTI, gastrointestinal tract
- Endocarditis uncommon, but may cause significant morbidity (mortality)
- Arthritis is uncommon, usually with knee involvement or spondylitis (sacro-ileitis)
- Pulmonary disease with pneumonia ± effusions may occur
- Brucellosis of the spine may occur and present as a mass (absecess) lesion
- Chronic (Progressive) Disease
- At least 1 year nonspecific symptoms
- May have relapsing course, especially with arthritis
- Veterinarians are at particular risk for hypersensitivity reaction
C. Diagnosis
- Culture (usually bone marrow) is definitive method (may require prolonged incubation)
- Polymerase Chain Reaction (PCR)
- Fast method applicable to any body tissue
- Results may be positive within 10 days of inoculation
- Real-time PCR is being developed and may require only 30 minutes for diagnosis
- Multiplex PCR is also being developed for multiple organism identification
- Brucella Agglutination Test
- Titer at least 1:160 is positive
- IgM Ab rise usually within 1 week with peak and 3 months
- IgG may disappear within 1 year but requires 1-2 months to increase
- Cholera vaccination may give false positive
- Some cross-reaction with Francisella tularensis and Yersinia enterocolitica
- May be mistaken for moraxella species, particularly M. phenylpurvica [6]
- Antinuclear antibody (ANA) may be elevated [3]
- Bone marrow with non-caseating granulomas
D. Treatment [1,5]
- Mild Cases
- Doxycycline 100mg po or IV bid x 6 weeks in mild cases
- Ofloxacin 400mg bid or ciprofloxacin 500mg bid both for 6 weeks also for mild cases
- Rifampin 600mg per day may be added to either quinolone or doxycycline
- TMP/SMX (Bactrim®, Septra®) DS tid x 4-6wks po alternative (increased relapse rate)
- Moderate to Severe Cases
- Doxycycline + rifampin (600-900mg/d) as effective as doxycycline + streptomycin
- Tetracycline 7.5mg/kg q6° x 4-6wks + streptomycin 15mg/kg q12hr x 2 weeks
- For patients with spondylitis, doxycycline + streptomycin is preferred
- Gentamicin 1.5mg q8 hours can be substituted for streptomycin
- Ciprofloxacin + doxycycline or rifampin
- Consider prednisone 60mg/d with rapid 5-7d taper in patients with severe debilitation
- Symptomatic therapy for bachache and headache
References
- Pappas G, Akritidis N, Bosilkovski M, Tsianos E. 2005. NEJM. 352(22):2325
- Dames S, Tonnerre C, Saint S, Jones SR. 2005. NEJM. 352922):2338 (Case Discussion)
- Noble JT and Mark EJ. 2002. NEJM. 347(3):200 (Case Record)
- Tan JS. 1997. Arch Intern Med. 157(17):1933
- Drugs and Vaccines Against Biological Weapons. 1999. Med Let. 41(1046):15
- Kontoyiannis DP and Versalovic J. 2001. NEJM. 344(26):2009 (Case Record)